BLU

BELLUS Health Inc. [BLU] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BLU Stock Summary

In the News

BLU Financial details

Company Rating
-
Market Cap
1.87B
Income
-108.19M
Revenue
3.17B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
74
Optionable
No
Shortable
Yes
Earnings
08 Aug 2023
P/E
-21.51
Forward P/E
-
PEG
5.15
P/S
124656.2
P/B
5.06
P/C
-
P/FCF
-20.96
Quick Ratio
32.13
Current Ratio
33.42
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.52
EPS next Y
-
EPS next Q
-
EPS this Y
-26.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
29.67%
Revenue last 5Y
-9.04%
Revenue Q/Q
8.47%
EPS Q/Q
103.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-23%
ROE
-24%
ROC
-0.24%
Gross Margin
100%
Oper. Margin
-602047%
Profit Margin
-578587%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.38-14.76
52W High
-
52W Low
-
RSI
-
Rel Volume
0.53
Avg Volume
5.38M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-0.27898
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
META
0YXG.L
MSFT
FB2A.DE
AMZN
Same Sector
SUPN
8037.HK
ALACT.PA
UFPT
NTRA
Check Those
JSWSTEEL.NS
RAMCOIND.NS
0531.HK
051900.KS
002686.SZ
Similar Market Cap
0R0U.L
002872.SZ
3909.T
002134.SZ
HCXZ

Company Profile

Healthcare Biotechnology
  • Volume Average 5.38M
  • Market Capitalization 1.87B
  • Employee 74
  • CEO Mr. Roberto Francesco Bellini
  • Headquarters Laval,QC,CA
  • IPO Date 2000-10-27
  • Website https://www.bellushealth.com

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.